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Abstract
Background: The first meningococcal serogroup C (MenC) conjugate vaccine was licensed in 1999 and introduced
in the United Kingdom. Countries that have implemented the MenC vaccine since then in their national
immunisation programmes use different schedules. Nevertheless, all involved countries seem to experience
substantial declines in the incidence of MenC disease.
Discussion: Since 2001, the MenC conjugate vaccine has been implemented in the Netherlands by offering a
single dose to all children aged 14 months. Prior to the introduction of the vaccine into the national immunisation
programme, a catch-up vaccination campaign was initiated in which a single dose of the MenC conjugate vaccine
was offered to all children aged from 14 months up to and including 18 years. Since then, there has been no
report of any case of MenC disease among immunocompetent vaccinees. Administration of a single dose of MenC
conjugate vaccine after infancy could be beneficial considering the already complex immunisation schedules with
large numbers of vaccinations in the first year of life. The present paper deals with the advantages and critical
aspects of a single dose of the MenC conjugate vaccine.
Summary: A single dose of MenC conjugate vaccine at the age of 14 months in combination with a catch up
vaccine campaign appeared to be a successful strategy to prevent MenC disease in the Netherlands, thereby
confirming that a single dose of the vaccine could sufficiently protect against disease. Nevertheless, this approach
can only be justified in countries with a relatively low incidence of serogroup C meningococcal disease in the first
year of life. Furthermore, a good surveillance programme is recommended for timely detection of vaccine
breakthroughs and outbreaks among non-vaccinees, since long-term protection after a single dose in the second
year of life cannot currently be guaranteed.
Background
Neisseria meningitidis is a major cause of invasive bac-
terial infections worldwide [1]. The highest incidence
rate of meningococcal serogroup C (MenC) disease is in
children aged 2 years or younger and in the age group
of 14 to 20 years [2]. Efforts to control infections with
N. meningitidis have been aimed at the development of
effective meningococcal vaccines and subsequent imple-
mentation in appropriate vaccination schedules. In 1999,
an efficacious conjugate vaccine against MenC disease,
consisting of serogroup C capsule polysaccharide conju-
gated to tetanus toxoid as carrier protein, has been
licensed in Europe and has been used widely ever since.
However, in the absence of randomised controlled trials
on efficacy that support a specific vaccination schedule,
each country has its own scheme with respect to the
MenC conjugate vaccine (Table 1) [3]. In general,
regardless of the vaccination schedule that has been fol-
lowed, all countries that implemented the MenC conju-
gate vaccine in their programme experienced substantial
declines in the incidence of MenC disease [4]. At pre-
sent, not all European countries have implemented the
MenC conjugate vaccine in their national immunisation
programmes, such as Scandinavia, and most Eastern
European countries. For the countries that have
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commonly used vaccination schedules are 2 doses in
first year of life and a booster in the second year of life
or 1 dose in the second year of life with possibly an
additional booster later in life. The present paper deals
with the advantages and critical aspects of a single dose
of the MenC conjugate vaccine in the second year of life
with the experience of the Netherlands as example.
Discussion
Implementation of MenC vaccination in the Netherlands
In the Netherlands, the increase in MenC disease in
2000-2002 was the reason to implement the MenC con-
jugate vaccine into the Dutch immunisation programme
(Table 2). In 2000, 105 patients (an annual incidence
rate of 0.7 per 100.000 inhabitants of the Netherlands)
with a culture-proven serogroup C meningococcal infec-
tion were reported and in 2001 this number increased
to 276 patients (an annual incidence rate of 1.7 per
100.000 inhabitants of the Netherlands). In the Spring
of 2002, just prior to the implementation of the MenC
vaccine into the immunisation programme, a vaccina-
tion campaign was initiated including all children aged
from 14 months up to and including 18 years was
started. Subsequently, the MenC vaccine, i.e. a
conjugated MenC vaccine with tetanus toxoid as carrier
protein, was introduced for children at the age of 14
months into the immunisation programme of the Neth-
erlands from September 2002 onwards.
During this vaccination campaign approximately 3.5
million vaccinations were given, which together with the
vaccinations given prior to the campaign resulted in a
vaccination rate of 94% of the target population. At pre-
sent, the vaccination rate among children receiving a
single MenC conjugate vaccine dose at the age of 14
months according to the Dutch immunisation pro-
gramme has been reported to be as high as ≥ 95% (birth
cohort 2007) [7].
Outcome of MenC vaccine implementation in the
Netherlands
In the Netherlands, surveillance of MenC disease is per-
formed by a central laboratory that receives nation-wide
meningococcal isolates from more than 90% of all cases
with invasive meningococcal disease. Strikingly, since
the introduction of MenC conjugate vaccine in the
Netherlands there has been no report of any case of
MenC disease among immunocompetent vaccinees
(Table 2). In addition, the MenC disease incidence
among non-vaccinees showed a clear reduction due to
Table 1 Current vaccination schedules with the MenC conjugate vaccine in European countries
Country Number of
doses
Current MenC vaccination schedule Source
Andorra 3 2, 4, and 18 months WHO
a
Austria 2 13 months (MenC) and 11-13 years
(MenACWY)
The Federal Ministry of Health, Austria
b
Belgium 1 15 months WHO
Cyprus 1 12-13 months WHO
France 1 12-24 months Ministry of labour, employment and health, France
c
Germany 1 11-23 months WHO
Greece 3 2, 4, and 15-18 months WHO
Iceland 2 6 and 8 months WHO
Ireland 3 4, 6, and 13 months WHO
Italy 3 3, 5, and 11-12 months and risk groups WHO
Luxembourg 1 ≥ 13 months WHO
Monaco 1 2 years WHO
Netherlands 1 14 months WHO
Portugal 3 3, 5, 15 months WHO
Slovenia - risk groups WHO
Spain 3 2, 4-6, 12-18 months Vaccine Advisory Committee of the Spanish Association of
Paediatrics
d
Switzerland 2 12-15 months and 11-15 years WHO
United
Kingdom
3 3, 4, 12-13 months Department of Health, United Kingdom
e
a http://apps.who.int/immunization_monitoring/en/globalsummary/scheduleselect.cfm
bhttp://www.bmg.gv.at/cms/home/attachments/1/4/0/CH1100/CMS1038913010412/impfplan_2011.pdf
chttp://www.sante.gouv.fr/IMG/pdf/Tableau_des_vaccinations_recommandees_chez_les_enfants_et_adolescents.pdf
dhttp://vacunasaep.org/profesionales/calendario-de-vacunaciones-de-la-aep-2011
ehttp://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_122401.pdf
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Page 2 of 6herd immunity. From 2004 onwards, a maximum of 2
cases of MenC disease per year occurred at the age < 1
year (all infant cases occurred at the age ≥ 6m o n t h s ,<
1 year). Apparently, the routine childhood vaccination
and the initial catch-up campaign resulted in a reduc-
tion of circulating serogroup C meningococci which in
turn has led to a decreased transmission. It is important
to note that replacement by meningococci with other
s e r o g r o u p s ,i . e .s e r o g r o u pA ,B ,Y ,W 1 3 5 ,w a sn o t
observed. On the contrary, the incidence of serogroup B
meningococcal disease decreased from 1998 onwards
and continued to decline since the introduction of the
MenC conjugate vaccine in 2002 [5]. However, this is
considered to be based on coincidence, since the MenC
vaccine does not induce cross-reactive immunity to
meningococcal serogroup B bacteria. This is confirmed
by a study in the United Kingdom, whereby the preva-
lence of carriage of meningococci associated with ser-
ogroup B disease was unaffected by the introduction of
the MenC conjugate vaccine [8]. As expected, in this
latter study a decline in prevalence of carriage of ser-
ogroup C meningococci was reported from 1999, the
year of introduction of MenC conjugate vaccine in UK.
This finding was consistent with the observed herd
immunity in the non-vaccinated teenage population in
the UK [8].
Duration of immune response afforded by MenC vaccine
implementation in the Netherlands
Recently, MenC-specific immunity before and after
implementation of the MenC conjugate vaccine in 2002
in the Netherlands has been analysed using two large
cross-sectional serum banks each obtained from a
nation-wide Dutch population [9]. These serum banks
contain samples from participants 0-79 years of age that
were collected in two cross-sectional serosurveillance
studies performed in 1995/6 and 2006/7 [10,11]. From
these serum banks, polysaccharide specific IgG concen-
trations against serogroup C meningococci and func-
tional antibody titers obtained with the SBA have been
determined and described earlier [9]. Here we show the
SBA titres from respectively 735 and 1220 serum samples
before and after the introduction of the MenC conjugate
vaccine (Table 3). These data illustrate that, more than 4
years after vaccination (serum bank 2006/7), the MenC-
specific SBA titres were still remarkably high (SBA geo-
mean titre (GMT) ≥ 8) in individuals who were vacci-
nated at the age of 5 year or older during the vaccination
campaign (aged 9/10 years in 2006/7) (Table 3). A single
MenC conjugate vaccine administration above 5 years of
age seems to induce persistent protective SBA antibody
levels, gradually increasing with age of vaccination. In
contrast, MenC-specific SBA levels in serum samples
from individuals that have been vaccinated against MenC
disease at the age of 14 months, i.e. according to the
Dutch routine immunisation programme, showed a rapid
decline within a few years after vaccination. Apparently,
high functional antibody levels against serogroup C
meningococci persist longer in persons who were vacci-
nated at an age of 5 year or older [9].
These findings are consistent with results from a study
in the United Kingdom, showing that 5 years after
Table 2 MenC disease cases
a in the Netherlands per year, age group, and among vaccinees
Year Total Incidence rate
b Age groups
0-11 mths 1-4 yrs 5-9 yrs 10-14 yrs 15-19 yrs 20-24 yrs 25-29 yrs ≥ 30 yrs among vaccinees
2000 105 0.7 2 22 15 11 18 9 4 24 n.a.
2001 276 1.7 23 50 27 39 65 15 9 48 n.a.
2002
c 222 1.4 13 39 30 26 47 17 5 45 0
c
2003
d 42 0.3 11 6 0 1 0 6 0 18 0
2004 17 0.1 1 1 1 0 0 1 2 11 0
2005 4 0.03 0 0 0 0 0 0 0 4 0
2006 4 0.03 0 1 0 0 0 0 0 3 0
2007 9 0.06 2 0 1 0 1 1 0 4 0
2008 11 0.07 2 0 0 0 0 0 1 8 0
2009 10 0.06 1 1 0 0 1 0 2 5 0 (1)
e
2010 6 0.04 2 0 0 0 2 0 0 2 0 (1)
e
Surveillance data 2000-2009 are obtained from annual reports “Bacterial Meningitis in the Netherlands” published by “Netherlands Reference Laboratory for
Bacterial Meningitis” [5]. Data from 2010 are not published yet
n.a.; not applicable
a MenC disease cases are defined as culture and/or PCR-proven presence of MenC bacteria in cerebrospinal fluid and/or blood
b Incidence rate is defined as the annual incidence rate of MenC disease per 100.000 inhabitants of the Netherlands
c In the Netherlands, MenC conjugate vaccine was introduced in Spring 2002
d The case fatality rate (CFR) calculated from 58 patients with MenC disease cases occurring between January 2003-May 2005 was 5.2% [6]
e One case of MenC disease occurred in a vaccinated 16 years old female (2009), and one case in a vaccinated 19 years old male (2010). Both persons had an
immune disorder
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older exhibited higher functional (SBA) antibody levels
against serogroup C meningococci compared to younger
children [12]. Although, at present SBA is the best cor-
relate of protection for evaluating the immune response
to meningococcal serogroup C vaccines, for long-term
protection SBA levels alone may not be ideal [13]. A
better predictor for long-term protection may be a com-
bination of SBA levels with the number of MenC-speci-
fic memory B cells [14]. At present, failures of long-
term protection in children immunised with a single
dose of MenC conjugate vaccine at the second year of
life have not been documented [3]. The question that
thus remains is whether the existing antibody response
and/or B cell memory response in the individuals vacci-
nated with a single dose at the age of 14 months will be
strong enough to prevent disease in case of exposure to
serogroup C meningococci at later ages. High SBA levels
may be necessary, because meningococci have the
potential of rapid multiplication leading to fast progres-
sion of MenC disease [15,16]. This is probably why
some countries (i.e. Austria and Switzerland) have
implemented a booster dose at adolescent age in addi-
tion to the vaccine dose in the second year of life (Table
1). So far, no breakthroughs of MenC disease have
occurred in immunocompetent vaccinated individuals in
the Netherlands. This is most probably due to dimin-
ished circulation of serogroup C meningococci as a con-
sequence of herd immunity induced by vaccination. On
the other hand, it might be that all vaccinated indivi-
duals are protected, despite the low SBA levels in those
who have been vaccinated at younger ages.
Implementation of the MenC vaccine in other countries
MenC vaccination in first year of life
In 1999, the MenC conjugate vaccine was introduced
nation-wide in the United Kingdom as first country in
Europe using three different MenC conjugate vaccines.
The vaccination scheme of the UK was three doses at
infancy, at the age of 2, 3 and 4 months. In Ireland and
Spain, similar MenC vaccination schedules were imple-
mented with three doses in the first year of life. In 2006,
the MenC vaccination schedule of the UK was altered
into the three dose schedule at 3, 4 and 12-13 months
of age. This decision was based upon the evidence-based
assumption that a booster with MenC conjugate vaccine
in the second year of life is needed to maintain protec-
tion against MenC disease after infancy and that two
Table 3 Serum bactericidal antibody (SBA) titres from serum samples obtained before and after the introduction of
the MenC conjugate vaccine [9]
Age Pre-introduction MenC vaccine (1995/6) Post-introduction MenC vaccine (2006/7)
No. samples SBA-GMT (95% CI) % samples SBA ≥ 8 No. samples SBA-GMT (95% CI) % samples SBA ≥ 8
0-7 mths 3 2 (NA) 0 59 2 (n.a.) 0
8-14 mths 13 2.1 (1.9-2.4) 0 62 2.4 (1.9-3.0) 3.2
15-24 mths 18 2.0 (NA) 0 27 131.3 (64.5-267.5) 92.6
2 yrs 24 2.0 (NA) 0 42 13.1 (8.3-20.8) 61.9
3-4 yrs 42 2.1 (1.9-2.4) 2.6 106 5.4 (3.8-7.7) 30.2
5-6 yrs 34 2.8 (1.6-4.7) 6 49 5.2 (3.4-7.8) 28.6
7-8 yrs 43 3.4 (2.2-5.2) 11.2 56 5.1 (3.7-7.1) 33.9
9-10 yrs
a 27 3.0 (1.3-6.9) 11.3 73 9.4 (5.8-15.2) 45.2
11-12 yrs 31 2.5 (1.4-4.5) 8.4 72 20.0 (12.4-32.2) 61.1
13-14 yrs 34 5.6 (2.1-14.8) 23.5 65 23.5 (15.9-34.6) 69.2
15-16 yrs 38 3.3 (2.1-5.1) 16.3 55 57.9 (36.7-91.1) 81.8
17-18 yrs 25 3.6 (1.8-7.1) 11.7 43 89.8 (58.4-138.0) 86
19-21 yrs 21 2.6 (1.9-3.5) 5.9 88 159.6 (109.1-233.4) 95.5
22-25 yrs 38 6.2 (3.1-12.4) 26.1 104 4.2 (9.1-22.6) 49
26-30 yrs 56 4.6 (2.1-10.0) 24.5 69 4.2 (3.1-5.9) 26.1
31-39 yrs 66 4.7 (3.8-5.8) 22.5 58 3.6 (2.1-6.0) 19
40-49 yrs 65 5.3 (4.0-6.9) 26 49 4.1 (2.5-6.7) 20.4
50-59 yrs 59 4.5 (3.9-5.2) 19.2 52 4.1 (2.5-6.6) 21.2
60-69 yrs 51 5.9 (3.0-11.5) 29.5 54 3.2 (2.7-3.7) 18.5
70-79 yrs 48 3.6 (2.1-6.1) 17.1 37 3.6 (2.5-5.4) 21.6
Total 736 4.3 (3.3-5.5) 19.7 1220 10.2 (8.9-11.7) 43.0
n.a.; not applicable
95% CI; 95% confidence interval
a Individuals who were vaccinated at the age of 5 year during the vaccination campaign are aged 9-10 years in 2006/7
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response [17,18]. At present, the vaccination schemes in
Ireland and Spain have also been adapted accordingly
with two doses of the MenC conjugate vaccine in the
first year of life and a third booster dose in the second
year of life. A comparable vaccination scheme is imple-
mented in Andorra, Greece and Italy (Table 1). Results
from the different immunisation schedules that have
been used in Canada revealed that multiple doses in
early infancy provides little additional benefit over pro-
grammes starting with 1 dose at the age of 12 months
[19].
MenC vaccination in second year of life
At present, apart from the Netherlands, several other
countries, such as Belgium, Cyprus, France, Germany,
Luxembourg, and Monaco, have implemented a vaccina-
tion scheme with a single dose in the second year of life
(Table 1). However, this approach can only be justified
in countries with a relatively low incidence of serogroup
C meningococcal disease in the first year of life, which
was the case in the Netherlands prior to introduction of
the MenC conjugate vaccine (< 10% of MenC disease
cases occurred in infancy; Table 2). Recently, Austria
and Switzerland have introduced an additional booster
dose in teenagers besides the primary single dose in the
second year of life. This vaccination schedule anticipates
the observed waning immunity found after 1 dose in the
second year of life.
The ideal immunisation schedule should aim at a
maximal level of effectiveness with a minimum number
of doses needed. A single vaccination in the second year
of life might be sufficient for adequate protection,
whereas a minimum of 2 doses seems necessary when
starting in early infancy [17,18]. The immune system of
younger infants is not fully developed. For example, a
conjugated Hib vaccine induced a significantly lower
antibody response at 2-3 months of age when compared
to 6 months or later [20]. For this reason, administra-
tion of MenC conjugate vaccine after infancy, such as
has been implemented in the Netherlands, could be
beneficial. In addition, most national immunisation pro-
grammes includes already a large number of vaccina-
tions in the first year of life. This makes the
introduction of newly available vaccines at infancy, such
as against rotavirus, increasingly difficult, while there are
still several new vaccines under development for this
young age group, such as vaccines against serogroup B
meningococci and respiratory syncytial virus.
Summary
Despite the fact that different schedules have been
used for implementing the MenC conjugate vaccine, all
involved countries seem to experience substantial
declines in the incidence of MenC disease [4]. In the
Netherlands, there has been no report of any case of
MenC disease among immunocompetent vaccinees,
s i n c et h ei n t r o d u c t i o no fas i n g l ed o s eo ft h eM e n C
conjugate vaccine in the second year of life. Although
no data on nasopharyngeal carriage rates before and
after immunisation are available, it is likely that the
combination of this introduction together with the vac-
cine campaign, in which a single vaccine dose was
offered to all children aged from 14 months up to and
including 18 years, has led to a major reduction of cir-
culating serogroup C meningococci. The herd immu-
nity that was established has also led to a significant
reduction of serogroup C meningococcal disease
among non-vaccinees. Nevertheless, it had been shown
that individuals vaccinated at the age of 14 months
w i t has i n g l ed o s eo ft h eM e n Cc o n j u g a t ev a c c i n e
showed a rapid decline in (functional) antibody levels
against serogroup C meningococci within a few years
after vaccination. For this reason, when applying this
vaccination scheme, i.e. a single dose in the second
year of life without an addition booster dose, it is
important to have a solid surveillance programme, in
which the number of patients with serogroup C
meningococcal disease is carefully being monitored in
order to determine long-term vaccine protection. This
will allow timely detection of vaccine breakthroughs
and outbreaks among non-vaccinees, making a timely
and appropriate intervention possible, such as deciding
to administer a booster vaccination when needed to
guarantee protection during periods of susceptibility in
the second decade of life.
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